Functional consequences of decreased RNA expression of certain GABA(A) receptor subunits in fragile X patients using Positron Emission Tomography and [11C]flumazenil. - PET-FRAX-GABA
- Conditions
- Fragile X syndrome is the most common form of inherited mental retardation with a prevalence of 1/4000 males and 1/6000 females. Patients are characterized by a mild to severe form of cognitive impairment and light dysmorphic features. Autism-like behaviour, hyperactivity and epilepsy can also be associated with the disease. On the molecular level the disease is caused by a dynamic mutation of a CGG repeat in the 5' UTR of the FMR1 gene.
- Registration Number
- EUCTR2008-003287-18-BE
- Lead Sponsor
- niversity Antwerp
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Male
- Target Recruitment
- Not specified
Controls:
Males between 18-50 years old, general good health after physical examination and routine laboratory analysis, normal T1 and T2 brain MRI, body weight.
Patients:
Males between 16-50 years old, need to be approved by the investigators to undergo a 60 minutes PET imaging study.
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Controls and patients:
Drug abuse, hypersensitivity to drugs or flumazenil or benzodiazepines.
No history of other neurological or psychiatric abnormalities or any other major internal abnormality.
Medication which interacts with the GABA-system, in particular sleep enhancing medication, is not allowed within two weeks before and after the study, neither
drinking more than 3 caffein-containing glasses.
Current smokers (more than 5 sigarettes per day) and smokers who quitted less than three months ago will be excluded.
Alcohol is prohibited as from 2 days before the beginning of the study.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method